title: [Position hopeless lost--Heinrich Dreuw's lonely struggle against syphilis and Salvarsan].
abstract: The invention of Salvarsan (Triaminotrihydroxy-arsenobenzol) in 1910 meant a revolution in the medical treatment. Chemotherapy was born and its founder Paul Ehrlich is still famous for his experimental work. In medical history mostly successes, not widespread discussions about misuse or failing of the new drug were. The Berlin doctor Heinrich Dreuw was a key figure in these debates. He and his colleagues presented evidence that Salvarsan was not an effective drug and just an expensive placebo, which helped pharmaceutical trusts earning more money. Dreuw even attacked state medical branches for infringement against patients. At last doubts about Salvarsan never disappeared.
authors.affiliation: Institut für transkulturelle Gesundheitswissenschaften, Europa Universität Viadrina, Frankfurt/Oder. mildenberger@europa-uni.de
authors.forename: Florian
authors.initials: F
authors.lastname: Mildenberger
mesh_terms: D000993:Antitreponemal Agents / Q000266:history*; D001153:Arsphenamine / Q000266:history*; D004345:Drug Industry / Q000266:history*; D005858:Germany; D049673:History, 20th Century; D006801:Humans; D009324:Naturopathy / Q000266:history*; D013587:Syphilis / Q000266:history*; D017211:Treatment Failure
chemical_list: D000993:Antitreponemal Agents; D001153:Arsphenamine